Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of intravenous immune globulin for mild to moderate Alzheimer's disease
2011-000914-21Phase 3Terminated
- Sponsor
- Baxter International Inc.
- Start
- Sep 2011
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing IGIV 10% arm with Placebo arm (2 arms). Primary endpoints: Alzheimer's Disease Assessment Scale cognitive subscale and Functional activities. Started Sep 2011; status: terminated.
02
Drugs
IgPro10
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2011-000914-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000914-21.